About us02

We design and develop a new class of powerful therapeutics for the treatment of severe diseases. Our plug-and-play platform substantially reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics for chronic inflammation and cancer.

Management

Board

Advisors

David Urech

David Urech

CSO & Co-CEO

David is a co-founder of Numab. From 2004 until 2010, David was at Esbatech, as Head of Research & Development. He designed Esbatech’s antibody discovery platform, and was responsible for the discovery and preclinical development of ESBA1008 (now RTH258), a best-in-class anti-VEGF scFv for…

David is a co-founder of Numab. From 2004 until 2010, David was at Esbatech, as Head of Research & Development. He designed Esbatech’s antibody discovery platform, and was responsible for the discovery and preclinical development of ESBA1008 (now RTH258), a best-in-class anti-VEGF scFv for the treatment of age-related macular edema. His work on the pharmacokinetic properties of antibody fragments led to the development of ESBA105, a TNF-inhibitory scFv – the first antibody fragment to be applied topically by eye drops. David is an inventor on numerous patents and patent applications and has published widely in leading peer-reviewed journals. David holds an MSc in Molecular Biology and Neurosciences from the University of Zurich, and a PhD in Biochemistry from the Biocenter in Basel.

Oliver Middendorp

Oliver Middendorp

CBO & Co-CEO

Oliver is a co-founder of Numab. From 2004 until 2010, he was at Esbatech as Head of Alliance Management and responsible for intellectual property. After Esbatech was acquired by Alcon in September 2009, Oliver became a member of Alcon’s R&D Alliance Group, tasked with search, evaluation,…

Oliver is a co-founder of Numab. From 2004 until 2010, he was at Esbatech as Head of Alliance Management and responsible for intellectual property. After Esbatech was acquired by Alcon in September 2009, Oliver became a member of Alcon’s R&D Alliance Group, tasked with search, evaluation, negotiations and alliance management of collaborations, while remaining Head of Alliance Management at Esbatech, and a member of the Esbatech Management. Oliver studied molecular biology and immunology at the University of Zurich and received his PhD in biochemistry from the University of Basel in 2004.

Peter Lichtlen

Peter Lichtlen

VP & Chief Medical Officer

Peter is a co-founder of Numab. He holds an MD as well as a PhD in Molecular Biology from the University of Zurich. In 2000 Peter joined ESBATech AG to hold various positions in preclinical and clinical research. In 2004 he was appointed Medical Director and Head of Clinical Research and…

Peter is a co-founder of Numab. He holds an MD as well as a PhD in Molecular Biology from the University of Zurich. In 2000 Peter joined ESBATech AG to hold various positions in preclinical and clinical research. In 2004 he was appointed Medical Director and Head of Clinical Research and Development, leading several preclinical development projects with antibody fragments in oncology, inflammatory and neurodegenerative diseases. He developed ESBATech’s “body compartment concept” aimed at the optimal therapeutic exploitation of the pharmacokinetic properties of antibody fragments. He designed and led clinical development programs in ophthalmology and rheumatology with ESBA105 and ESBA1008, TNF-inhbitory and VEGF-inhibitory antibody fragments, respectively. Peter joins from Sucampo, where from 2011 he was Senior Medical Officer and Vice President European Operations. He co-authored a great number of peer-reviewed publications.

Tea Gunde

Tea Gunde

Vice President Discovery and Pharmacology

Before joining Numab in 2011, Tea was Head of pharmacokinetics & pharmacodynamics at Esbatech from 2004 until 2011. She led the development of bio-analytical methods in drug discovery and development, as well as the pharmacodynamic and pharmacokinetic characterization of antibody fragment…

Before joining Numab in 2011, Tea was Head of pharmacokinetics & pharmacodynamics at Esbatech from 2004 until 2011. She led the development of bio-analytical methods in drug discovery and development, as well as the pharmacodynamic and pharmacokinetic characterization of antibody fragment lead candidates. Tea led preclinical discovery and development projects in the field of ophthalmology, and was instrumental in the discovery and the development of ESBA1008 (now RTH258), a best-in-class anti-VEGF scFv for the treatment of age-related macular edema. Tea is an inventor on a number of patents and patent applications and has published in leading peer-reviewed journals. Tea holds an MSc in Molecular Biology and Immunology from the University of Zurich, and obtained her PhD in Molecular Biology from the University of Zurich in 2004.

Sebastian Meyer

Sebastian Meyer

Vice President Protein Engineering & CMC

Sebastian joined Numab in 2012 and is responsible for the engineering, manufacturing process development and biophysical characterization of the company’s antibody-based therapeutics. Before joining Numab, Sebastian headed the downstream processing and analytics unit of ESBATech, focusing on…

Sebastian joined Numab in 2012 and is responsible for the engineering, manufacturing process development and biophysical characterization of the company’s antibody-based therapeutics. Before joining Numab, Sebastian headed the downstream processing and analytics unit of ESBATech, focusing on process development and characterization of novel scFv drug candidates in Phase I/II of clinical development. Prior to that, Sebastian was a bioprocess development group leader at Cytos Biotechnology. During his post-graduate studies, Sebastian investigated the structure and function of chloride channels and transporters. Sebastian graduated with a degree in Biochemistry from the University of Hamburg and obtained his PhD from the University of Zurich.

Roland Helfenstein

Roland Helfenstein

Vice President Finance

Roland joined Numab in 2011. He started his career in 1997 as a controller in the sports goods industry. From 2004 until 2011 he worked in the banking industry in Switzerland and Asia with positions in marketing, customer experience management, process management and information technology.…

Roland joined Numab in 2011. He started his career in 1997 as a controller in the sports goods industry. From 2004 until 2011 he worked in the banking industry in Switzerland and Asia with positions in marketing, customer experience management, process management and information technology. Roland holds a Master’s degree in Economics and Business Administration and a Certificate of Advanced Studies in Corporate Finance, both from the University of Zurich.

Management

Board

Advisors

David Urech

Chairman Numab Innovation

David is a co-founder of Numab. From 2004 until 2010, David was at Esbatech, as Head of Research & Development. He designed Esbatech’s antibody discovery platform, and was responsible for the discovery and preclinical development of ESBA1008 (now RTH258), a best-in-class anti-VEGF scFv for…

David is a co-founder of Numab. From 2004 until 2010, David was at Esbatech, as Head of Research & Development. He designed Esbatech’s antibody discovery platform, and was responsible for the discovery and preclinical development of ESBA1008 (now RTH258), a best-in-class anti-VEGF scFv for the treatment age-related macular edema. His work on the pharmacokinetic properties of antibody fragments led to the development of ESBA105, a TNF-inhibitory scFv – the first antibody fragment to be applied topically by eye drops. David is an inventor on numerous patents and patent applications and has published widely in leading peer-reviewed journals. David holds an MSc in Molecular Biology and Neurosciences from the University of Zurich, and a PhD in Biochemistry from the Biocenter in Basel.

Oliver Middendorp

Chairman Numab Therapeutics

Oliver is a co-founder of Numab. From 2004 until 2010, he was at Esbatech as Head of Alliance Management and responsible for intellectual property. After Esbatech was acquired by Alcon in September 2009, Oliver became a member of Alcon’s R&D Alliance Group, tasked with search, evaluation,…

Oliver is a co-founder of Numab. From 2004 until 2010, he was at Esbatech as Head of Alliance Management and responsible for intellectual property. After Esbatech was acquired by Alcon in September 2009, Oliver became a member of Alcon’s R&D Alliance Group, tasked with search, evaluation, negotiations and alliance management of collaborations, while remaining Head of Alliance Management at Esbatech, and a member of the Esbatech Management. Oliver studied molecular biology and immunology at the University of Zurich and received his PhD in biochemistry from the University of Basel in 2004.

Mark G. Egan

Mark Egan is an investment-banking veteran who between 1962 and 1989 made his career at Hornblower & Weeks, Kuhn Loeb & Co, and Lehman Brothers. Since 1989 Mark is president, chairman and owner of Marlin Capital. Marlin Capital is the general partner of the Private Investment Fund of…

Mark Egan is an investment-banking veteran who between 1962 and 1989 made his career at Hornblower & Weeks, Kuhn Loeb & Co, and Lehman Brothers. Since 1989 Mark is president, chairman and owner of Marlin Capital. Marlin Capital is the general partner of the Private Investment Fund of which Mark is the largest limited partner.

Fritz Kunz

Fritz Kunz is a seasoned pharmaceutical industry executive, who started his career at Sandoz Pharma in 1971. In 1992, Fritz was appointed chief financial officer at Stratec Medical, and from 1994 to 1998 he was CEO and a member of the Board of Directors of Institute Straumann. He was a member of…

Fritz Kunz is a seasoned pharmaceutical industry executive, who started his career at Sandoz Pharma in 1971. In 1992, Fritz was appointed chief financial officer at Stratec Medical, and from 1994 to 1998 he was CEO and a member of the Board of Directors of Institute Straumann. He was a member of the Board of Directors of Speedel, and Chairman from 2000 to 2008, when Novartis acquired the company. He is a member of the Board of Sentec. Fritz holds a PhD in Bio-organic Chemistry from the Swiss Federal Institute of Technology (ETH), Zurich, and was a post-doctoral fellow at Yale.

Peter Lichtlen

Peter is a co-founder of Numab. He holds an MD as well as a PhD in Molecular Biology from the University of Zurich. In 2000 Peter joined ESBATech AG to hold various positions in preclinical and clinical research. In 2004 he was appointed Medical Director and Head of Clinical Research and…

Peter is a co-founder of Numab. He holds an MD as well as a PhD in Molecular Biology from the University of Zurich. In 2000 Peter joined ESBATech AG to hold various positions in preclinical and clinical research. In 2004 he was appointed Medical Director and Head of Clinical Research and Development, leading several preclinical development projects with antibody fragments in oncology, inflammatory and neurodegenerative diseases. He developed ESBATech’s “body compartment concept” aimed at the optimal therapeutic exploitation of the pharmacokinetic properties of antibody fragments. He designed and led clinical development programs in ophthalmology and rheumatology with ESBA105 and ESBA1008, TNF-inhbitory and VEGF-inhibitory antibody fragments, respectively. Peter joins from Sucampo, where from 2011 he was Senior Medical Officer and Vice President European Operations. He co-authored a great number of peer-reviewed publications.

Management

Board

Advisors

James Egan

James Egan has been a life sciences executive since 1984. As international counsel at Abbott Laboratories and as a Business Development executive at G. D. Searle & Co., Jamie facilitated over two dozen transnational licensing transactions, including regional rights to Celebrex®(celecoxib),…

James Egan has been a life sciences executive since 1984. As international counsel at Abbott Laboratories and as a Business Development executive at G. D. Searle & Co., Jamie facilitated over two dozen transnational licensing transactions, including regional rights to Celebrex®(celecoxib), and Biaxin®(clarithromycin), and global rights to PREZISTA®(darunavir).

As a C level biotech executive Jamie participated in the management and financing of start-up companies in the US, Switzerland and New Zealand. At Idenix he facilitated a transformational regional deal that enabled C-round financing and then executed a $2.9 billion strategic alliance with Novartis that enabled the company’s successful IPO in 2003. Idenix was acquired by Merck for $3.9 billion in 2014. As CBO at ESBATech Jamie facilitated its acquisition in 2009 by Novartis/Alcon for $589 million.

Jamie was COO of Sucampo Pharmaceuticals (NASDAQ: SCMP) from 2009 to 2013. He now consults for start-ups with first-in-class/best-in-class programs, and coordinates an investor group that invests in biotechs that seek to execute transformational deals.

Robert Kamen, PhD

Bob Kamen is an entrepreneur-in-residence at Third Rock Ventures with more than 30 years of experience in the pharmaceutical and biotechnology industries. He served as president of Abbott Bioresearch Center, where he oversaw the discovery and production of Humira®, the first fully human antibody…

Bob Kamen is an entrepreneur-in-residence at Third Rock Ventures with more than 30 years of experience in the pharmaceutical and biotechnology industries. He served as president of Abbott Bioresearch Center, where he oversaw the discovery and production of Humira®, the first fully human antibody to achieve marketing approval in the U.S. and Europe, and was a member of the Abbott Pharmaceuticals Executive Management Committee. Dr. Kamen also served as the president of BASF Bioresearch Corp. until it was acquired by Abbott Laboratories in 2001. Earlier in his career, Dr. Kamen led discovery at Genetics Institute, Inc. In 2005, Dr. Kamen co-founded BioAssets Development Corporation, a biotherapeutics company focusing on spinal diseases, acquired by Cephalon in 2010. Dr. Kamen is a director of Harbour Antibodies BV, Lycera Corp. and Opsonic Therapeutics, and an advisor to other biopharmaceutical companies. Dr. Kamen holds an undergraduate degree in biophysics from Amherst College and a PhD in biochemistry and molecular biology from Harvard University.

Masafumi Yoshimoto, PhD

Founder and president of PharmaBDL LLC, and board member of the Japan Pharma Licensing Association (JPLA) from 1997 until 2012, Dr. Yoshimoto is a highly respected authority in the Japanese pharmaceutical industry. In 2005-2006, he served as Chairman of Pharma Delegates, a voluntary healthcare…

Founder and president of PharmaBDL LLC, and board member of the Japan Pharma Licensing Association (JPLA) from 1997 until 2012, Dr. Yoshimoto is a highly respected authority in the Japanese pharmaceutical industry. In 2005-2006, he served as Chairman of Pharma Delegates, a voluntary healthcare industry association comprised of the vast majority of companies, individual executives, and others who provide services to the healthcare industry in Japan.

PharmaBDL provides business development and licensing consulting services to facilitate collaborations and transactions with Japanese pharmaceutical companies. Prior to founding PharmaBDL, Dr. Yoshimoto was for almost 40 years at Sankyo (now Daiichi Sankyo) in positions of increasing responsibility in drug design, research and development, and licensing. From 1996 until 2005 he was Director & Councilor of the Licensing Department.